CYSB2400016 | 人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products(原4) | Supplementary Application | 2024-01-12 | | Zhaoke Pharmaceutical (Hefei) Co Ltd | | | view |
CYSB2400015 | 人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products(原4) | Supplementary Application | 2024-01-12 | | Zhaoke Pharmaceutical (Hefei) Co Ltd | | | view |
CYSB2200211 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2022-08-23 | | Zhaoke Pharmaceutical (Hefei) Co Ltd | | | view |
CYSB2200212 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2022-08-22 | | Zhaoke Pharmaceutical (Hefei) Co Ltd | | | view |
CYSB1300094 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2013-05-31 | 兆科药业(合肥)有限公司 | Zhaoke Pharmaceutical (Hefei) Co Ltd | Certificate Issued | 2014-07-24 | view |
CYSB1300093 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2013-05-31 | 兆科药业(合肥)有限公司 | Zhaoke Pharmaceutical (Hefei) Co Ltd | Certificate Issued | 2014-07-24 | view |
CYSB1500092 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2015-06-01 | 兆科药业(合肥)有限公司 | Zhaoke Pharmaceutical (Hefei) Co Ltd | Certificate Issued | 2016-05-04 | view |
CYSB1500093 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2015-06-01 | 兆科药业(合肥)有限公司 | Zhaoke Pharmaceutical (Hefei) Co Ltd | Certificate Issued | 2016-05-04 | view |
CYSB2000051 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2020-04-04 | 兆科药业(合肥)有限公司 | Zhaoke Pharmaceutical (Hefei) Co Ltd | In Review | 2020-04-03 | view |
CYSB2000052 | 重组人干扰素α2b凝胶 | Recombinant Human Interferon α2b | Gel | Biological Products | Supplementary Application | 2020-04-04 | 兆科药业(合肥)有限公司 | Zhaoke Pharmaceutical (Hefei) Co Ltd | In Review | 2020-04-03 | view |